EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease

A Swaminathan iD, G M Borichevsky, C M Frampton, A S Day iD, M B Hampton, A J Kettle, R B Gearry

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae032 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von A Swaminathan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Feces, Biomarkers, Peroxidase. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Royal Australasian College of Physicians, New Zealand Society of Gastroenterology Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biomarkers have been proposed as surrogate treatment targets for the management of inflammatory bowel disease (IBD); however, their relationship with IBD-related complications remains unclear. This study investigated the utility of neutrophil biomarkers fecal calprotectin (fCal) and fecal myeloperoxidase (fMPO) in predicting a complicated IBD course.

Methods

Participants with IBD were followed for 24 months to assess for a complicated IBD course (incident corticosteroid use, medication escalation for clinical disease relapse, IBD-related hospitalizations/surgeries). Clinically active IBD was defined as Harvey-Bradshaw index >4 for Crohn’s disease (CD) and simple clinical colitis activity index >5 for ulcerative colitis (UC). Area under the receiver-operating-characteristics curves (AUROC) and multivariable logistic regression assessed the performance of baseline symptom indices, fCal, and fMPO in predicting a complicated disease IBD course at 24 months.

Results

One hundred and seventy-one participants were included (CD, n = 99; female, n = 90; median disease duration 13 years [interquartile range, 5-22]). Baseline fCal (250 μg/g; AUROC = 0.77; 95% confidence interval [CI], 0.69-0.84) and fMPO (12 μg/g; AUROC = 0.77; 95% CI, 0.70-0.84) predicted a complicated IBD course. Fecal calprotectin (adjusted OR = 7.85; 95% CI, 3.38-18.26) and fMPO (adjusted OR = 4.43; 95% CI, 2.03-9.64) were associated with this end point after adjustment for other baseline variables including clinical disease activity. C-reactive protein (CRP) was inferior to fecal biomarkers and clinical symptoms (pdifference < .05) at predicting a complicated IBD course. A combination of baseline CRP, fCal/fMPO, and clinical symptoms provided the greatest precision at identifying a complicated IBD course.

Conclusions

Fecal biomarkers are independent predictors of IBD-related outcomes and are useful adjuncts to routine clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte L1 Antigen ComplexFecesBiomarkersPeroxidaseCrohn DiseaseColitis, UlcerativeHumansFemaleMaleAdultMiddle AgedROC CurveSeverity of Illness IndexPrognosisProspective StudiesPredictive Value of TestsLogistic ModelsFollow-Up Studies

Stichwörter der Autor:innen

IBD managementbiomarkersfecal biomarkers

Substanzen

Leukocyte L1 Antigen ComplexBiomarkersPeroxidase

Autor:innen und Institutionen

  • Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
  • Department of Gastroenterology, Christchurch Hospital, New Zealand.
  • Mātai Hāora, Centre for Redox Biology and Medicine, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand.
  • Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand.

ORCID-Profile: A Swaminathan, A S Day

Förderung

  • Royal Australasian College of Physicians
  • New Zealand Society of Gastroenterology Research

Zitieren

APA

Swaminathan, A., Borichevsky, G. M., Frampton, C. M., Day, A. S., Hampton, M. B., Kettle, A. J., & Gearry, R. B. (2025). Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae032

Vancouver

Swaminathan A, Borichevsky GM, Frampton CM, Day AS, Hampton MB, Kettle AJ, et al. Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae032

BibTeX
@article{Swaminathan2025,
  author = {Swaminathan, A and Borichevsky, G M and Frampton, C M and Day, A S and Hampton, M B and Kettle, A J and Gearry, R B},
  title = {Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae032}
}
Kostenlos starten →